Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Belimumab 10 mg/kg plus standard therapy
BIOLOGICAL
3 trials
Sponsors
Human Genome Sciences Inc., a GSK Company
, GlaxoSmithKline
Conditions
Lupus Nephritis
Systemic Lupus Erythematosus
Phase 3
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Completed
NCT01639339
Human Genome Sciences Inc., a GSK Company
Lupus Nephritis
Start: 2012-07-12
End: 2020-03-12
Updated: 2021-03-19
Phase 4
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Completed
NCT01632241
Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
Start: 2013-02-19
End: 2019-01-28
Updated: 2021-09-08
Belimumab Assessment of Safety in SLE
Completed
NCT01705977
GlaxoSmithKline
Systemic Lupus Erythematosus
Start: 2012-11-27
End: 2022-08-10
Updated: 2024-07-15
Related Papers
Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.
2026-07-03
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a <i>post-hoc</i> summary of five phase 3 trials
Reumatismo
2025-11-26
#1672 Cost-effectiveness analysis of voclosporin vs mycophenolate or belimumab in the treatment of patients with lupus nephritis from the Spanish National Healthcare System perspective
Nephrology Dialysis Transplantation
2025-10-01
Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
UNC Libraries
2025-06-04
COMPLETE RENAL RESPONSES AND SAFETY FOR BELIMUMAB VERSUS PLACEBO IN A POST HOC MYCOPHENOLATE MOFETIL SUBGROUP WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
The Journal of Rheumatology
2025-05-20
1 citations
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Lupus
2025-05-05
2 citations
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
2024-09-01
7 citations
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
2024-08-26
15 citations
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
Lupus Science & Medicine
2024-05-01
2 citations
Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review
Current Therapeutic Research
2024-01-01
3 citations
Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial
Nephrology Dialysis Transplantation
2023-07-18
18 citations
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
2023-07-01
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
2023-07-01
1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)
Innate Immunity
2022-12-01
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
Clinical Journal of the American Society of Nephrology
2022-10-27
62 citations
PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis
2022-09-27
PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification
2022-09-27
PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis
2022-09-27
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
2022-09-02
31 citations
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
Lupus Science & Medicine
2022-09-01
1 citations
14 more papers not shown